End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.74 USD | 0.00% | +8.75% | -7.94% |
Feb. 22 | Notable Labs, Ltd. Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment | CI |
Jan. 09 | Top Premarket Gainers | MT |
Financials (USD)
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 16.23M |
---|---|---|---|---|---|
Net income 2023 * | -14M | Net income 2024 * | -14M | EV / Sales 2023 * | - |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-1.11
x | P/E ratio 2024 * |
-1.13
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 67.56% |
Latest transcript on Notable Labs, Ltd.
1 week | +8.75% | ||
Current month | +17.56% | ||
1 month | +22.11% | ||
3 months | -14.76% | ||
Current year | -7.94% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 1.8 | +3.45% | 46,546 |
24-03-26 | 1.74 | 0.00% | 65,418 |
24-03-25 | 1.74 | -8.90% | 90,773 |
24-03-22 | 1.91 | +11.70% | 140,705 |
24-03-21 | 1.71 | +6.87% | 101,387 |
End-of-day quote Nasdaq, March 25, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.94% | 16.23M | |
+3.17% | 108B | |
+9.77% | 104B | |
+6.58% | 23.66B | |
-11.62% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.13% | 16.19B | |
+4.61% | 13.72B | |
+34.88% | 12.22B |